Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 6 de 6
Filter
Add more filters










Database
Language
Publication year range
1.
Dev Biol ; 408(1): 109-25, 2015 Dec 01.
Article in English | MEDLINE | ID: mdl-26524254

ABSTRACT

Cerebellar granule neurons develop postnatally from cerebellar granule precursors (GCPs), which are located in the external granule layer (EGL) where they massively proliferate. Thereafter, GCPs become postmitotic, migrate inward to form the internal granule layer (IGL), further differentiate and form synapses with Purkinje cell dendrites. We previously showed that the Btg family gene, Tis21/Btg2, is required for normal GCP migration. Here we investigated the role in cerebellar development of the related gene, Btg1, which regulates stem cell quiescence in adult neurogenic niches, and is expressed in the cerebellum. Knockout of Btg1 in mice caused a major increase of the proliferation of the GCPs in the EGL, whose thickness increased, remaining hyperplastic even after postnatal day 14, when the EGL is normally reduced to a few GCP layers. This was accompanied by a slight decrease of differentiation and migration of the GCPs and increase of apoptosis. The GCPs of double Btg1/Tis21-null mice presented combined major defects of proliferation and migration outside the EGL, indicating that each gene plays unique and crucial roles in cerebellar development. Remarkably, these developmental defects lead to a permanent increase of the adult cerebellar volume in Btg1-null and double mutant mice, and to impairment in all mutants, including Tis21-null, of the cerebellum-dependent motor coordination. Gain- and loss-of-function strategies in a GCP cell line revealed that Btg1 regulates the proliferation of GCPs selectively through cyclin D1. Thus, Btg1 plays a critical role for cerebellar maturation and function.


Subject(s)
Cerebellum/growth & development , Cerebellum/physiopathology , Cyclin D1/metabolism , Motor Activity , Neoplasm Proteins/genetics , Aging/metabolism , Animals , Animals, Newborn , Apoptosis , Cell Count , Cell Differentiation , Cell Movement , Cell Proliferation , Cerebellum/pathology , G1 Phase Cell Cycle Checkpoints , Gene Deletion , Humans , Immediate-Early Proteins/metabolism , Medulloblastoma/pathology , Mice, Inbred C57BL , Mice, Knockout , Neoplasm Proteins/deficiency , Neoplasm Proteins/metabolism , Tumor Suppressor Proteins/metabolism
2.
Hippocampus ; 24(12): 1458-65, 2014 Dec.
Article in English | MEDLINE | ID: mdl-24990518

ABSTRACT

Post-transcriptional gene regulation mediated by microRNAs (miRNAs) is implicated in memory formation; however, the function of miR-92 in this regulation is uncharacterized. The present study shows that training mice in contextual fear conditioning produces a transient increase in miR-92 levels in the hippocampus and decreases several miR-92 gene targets, including: (i) the neuronal Cl(-) extruding K(+) Cl(-) co-transporter 2 (KCC2) protein; (ii) the cytoplasmic polyadenylation protein (CPEB3), an RNA-binding protein regulator of protein synthesis in neurons; and (iii) the transcription factor myocyte enhancer factor 2D (MEF2D), one of the MEF2 genes which negatively regulates memory-induced structural plasticity. Selective inhibition of endogenous miR-92 in CA1 hippocampal neurons, by a sponge lentiviral vector expressing multiple sequences imperfectly complementary to mature miR-92 under the control of the neuronal specific synapsin promoter, leads to up-regulation of KCC2, CPEB3 and MEF2D, impairs contextual fear conditioning, and prevents a memory-induced increase in the spine density. Taken together, the results indicate that neuronal-expressed miR-92 is an endogenous fine regulator of contextual fear memory in mice.


Subject(s)
Fear/physiology , Hippocampus/physiology , Memory/physiology , MicroRNAs/metabolism , Neurons/physiology , Animals , Cells, Cultured , Conditioning, Classical/physiology , Dendritic Spines/physiology , MEF2 Transcription Factors/metabolism , Mice, Inbred C57BL , MicroRNAs/antagonists & inhibitors , RNA-Binding Proteins/metabolism , Rats, Wistar , Symporters/metabolism , K Cl- Cotransporters
3.
J Alzheimers Dis ; 38(2): 281-93, 2014.
Article in English | MEDLINE | ID: mdl-23948942

ABSTRACT

One of the hallmarks of Alzheimer's disease (AD), the most common age-related neurodegenerative pathology, is the abnormal extracellular deposition of neurotoxic amyloid-ß (Aß) peptides that accumulate in senile plaques. Aß aggregates are toxic to neurons and are thought to contribute to neuronal loss. Evidence indicates that inflammation is involved in the pathophysiology of AD, and activation of glial cells by a variety of factors, including Aß, appears to be a central event. Among molecules produced during inflammation associated with neuronal death, CCL2, also known as monocyte chemotactic protein-1 (MCP-1), seems to be particularly important. Indeed, CCL2 levels are higher in the cerebrospinal fluid of patients with AD than in controls. In the present study, we demonstrated the protective effect of bindarit (which inhibits CCL2 synthesis) against both Aß25-35 and Aß1-42-induced toxicity in primary mixed neural cultures. Bindarit (30-500 µM) reversed cell death induced by Aß in a dose-dependent manner and reduced the transcription and release of CCL2 by astrocytes after Aß treatment, as revealed by qRT-PCR, ELISA, and immunofluorescence staining. Astroglial activation and CCL2 release was induced by ATP released by damaged neurons through interaction with P2X7 receptors present on astrocyte surface. CCL2, interacting with its cognate receptor CCR2, present on neuron surface, strongly contributes to the toxic activity of Aß. Bindarit was able to disconnect this neuro-glial interaction. Our results demonstrate the ability of bindarit to inhibit Aß-induced neuronal death and suggest the potential role of CCL2 inhibitors in the treatment of neuroinflammatory/neurodegenerative diseases.


Subject(s)
Chemokine CCL2/metabolism , Indazoles/pharmacology , Neurons/drug effects , Neuroprotective Agents/pharmacology , Propionates/pharmacology , Adenosine Triphosphate/pharmacology , Amyloid beta-Peptides/toxicity , Animals , Cell Survival/drug effects , Cerebral Cortex/cytology , Chemokine CCL2/genetics , Dose-Response Relationship, Drug , Embryo, Mammalian , Enzyme Inhibitors/pharmacology , Female , Gene Expression Regulation/drug effects , Neuroglia/drug effects , Neurons/ultrastructure , Peptide Fragments/toxicity , Pregnancy , Rats , Rats, Wistar
4.
J Alzheimers Dis ; 21(2): 445-70, 2010.
Article in English | MEDLINE | ID: mdl-20571215

ABSTRACT

Synapses are ultrastructural sites for memory storage in brain, and synaptic damage is the best pathologic correlate of cognitive decline in Alzheimer's disease (AD). Post-translational hyperphosphorylation, enzyme-mediated truncation, conformational modifications, and aggregation of tau protein into neurofibrillary tangles (NFTs) are hallmarks for a heterogeneous group of neurodegenerative disorders, so-called tauopathies. AD is a secondary tauopathy since it is pathologically distinguished by the presence of amyloid-beta (Abeta)-containing senile plaques and the presence of tau-positive NFTs in the neocortex and hippocampus. Here, we report that a 20-22 kDa NH2-truncated tau fragment is largely enriched in human mitochondria from cryopreserved synaptosomes of AD brains and that its amount in terminal fields correlates with the pathological synaptic changes and with the organelle functional impairment. This NH2-truncated tau form is also found in other human, not AD-tauopathies, while its presence in AD patients is linked to Abeta multimeric species and likely to pathology severity. Finally native, patient-derived, Abeta oligomers-enriched extracts likely impair the mitochondrial function by the in vitro production of 20-22 kDa NH2-tau fragments in mature human SY5Y and in rat hippocampal neurons. Thus our findings suggest that the mitochondrial NH2-derived tau peptide distribution may exacerbate the synapse degeneration occurring in tauopathies, including AD, and sustain the in vivo NH-2 tau cleavage inhibitors as an alternative drug discovery strategies for AD therapy.


Subject(s)
Alzheimer Disease/metabolism , Mitochondria/metabolism , Nerve Degeneration/metabolism , Neurons/metabolism , Synapses/metabolism , tau Proteins/metabolism , Alzheimer Disease/pathology , Animals , Cell Line, Tumor , Female , Hippocampus/cytology , Humans , Mitochondria/pathology , Nerve Degeneration/pathology , Neuroblastoma , Neurofibrillary Tangles/metabolism , Neurofibrillary Tangles/pathology , Neurons/pathology , Peptide Fragments/metabolism , Pregnancy , Rats , Rats, Wistar , Solubility , Synapses/pathology
5.
J Biol Chem ; 285(24): 18344-51, 2010 Jun 11.
Article in English | MEDLINE | ID: mdl-20395292

ABSTRACT

The amyloid precursor protein (APP) and its proteolytic product amyloid beta (Abeta) are associated with both familial and sporadic forms of Alzheimer disease (AD). Aberrant expression and function of microRNAs has been observed in AD. Here, we show that in rat hippocampal neurons cultured in vitro, the down-regulation of Argonaute-2, a key component of the RNA-induced silencing complex, produced an increase in APP levels. Using site-directed mutagenesis, a microRNA responsive element (RE) for miR-101 was identified in the 3'-untranslated region (UTR) of APP. The inhibition of endogenous miR-101 increased APP levels, whereas lentiviral-mediated miR-101 overexpression significantly reduced APP and Abeta load in hippocampal neurons. In addition, miR-101 contributed to the regulation of APP in response to the proinflammatory cytokine interleukin-1beta (IL-lbeta). Thus, miR-101 is a negative regulator of APP expression and affects the accumulation of Abeta, suggesting a possible role for miR-101 in neuropathological conditions.


Subject(s)
Amyloid beta-Protein Precursor/chemistry , Hippocampus/metabolism , MicroRNAs/metabolism , Neurons/metabolism , Animals , Argonaute Proteins , Base Sequence , Brain/embryology , Eukaryotic Initiation Factor-2/metabolism , Hippocampus/embryology , Interleukin-1beta/metabolism , Membrane Proteins/metabolism , Molecular Sequence Data , Rats , Rats, Wistar , Reverse Transcriptase Polymerase Chain Reaction , Sequence Homology, Nucleic Acid
6.
Mol Cell Neurosci ; 24(4): 1038-50, 2003 Dec.
Article in English | MEDLINE | ID: mdl-14697667

ABSTRACT

Che-1 is a recently identified human Rb binding protein that inhibits the Rb growth-suppressing function and regulates cell proliferation. Che-1 contacts the Rb and competes with HDAC1 for Rb-binding site, removing HDAC1 from the Rb/E2F cell cycle-regulated promoters. We have investigated the expression of Che-1 in neuronal cells and we showed that Che-1 directly interacts with Tau. Tau is a microtubule-associated protein involved in the assembly and stabilization of neuronal microtubules network that plays a crucial role modulating neuronal morphogenesis, axonal shape, and transport. In rat cerebellar granule neurons (CGNs) Che-1 partially colocalizes with Tau in the cytoplasm. Che-1 binds the amino-terminal region of Tau protein, which is not involved in microtubule interactions. Tau and Che-1 endogenous proteins coimmunoprecipitate from CGNs cellular lysates. In addition, Che-1/Tau interaction was demonstrated both in overexpressing COS-7 cells and CGNs by FRET analysis. Finally, we observed that Tau/Che-1 interaction is modulated during neuronal apoptosis.


Subject(s)
Apoptosis/physiology , Neurons/metabolism , Protein Kinases/metabolism , Retinoblastoma Protein/metabolism , tau Proteins/metabolism , Animals , Cerebellum/enzymology , Cerebellum/metabolism , Checkpoint Kinase 1 , Chlorocebus aethiops , Dogs , Humans , Mutation , Neurons/enzymology , Protein Binding/physiology , Rats , Rats, Wistar
SELECTION OF CITATIONS
SEARCH DETAIL
...